Global Colorectal Cancer Therapeutics Market Report and Forecast 2023-2031

Global Colorectal Cancer Therapeutics Market Report and Forecast 2023-2031


Global Colorectal Cancer Therapeutics Market Outlook


The global colorectal cancer therapeutics market size attained a value of USD 14.80 billion in 2022. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2023-2031 to attain a value of USD 25.87 billion by 2031.

Colorectal Cancer Therapeutics Market: Introduction


Colorectal cancer therapeutics refer to the different treatments and medications that are used to treat colorectal cancer, which is a type of cancer that affects the colon and rectum. Colorectal cancer is one of the most common types of cancer worldwide and is often treated with a combination of surgery, chemotherapy, and radiation therapy.

Surgery is the most common treatment for colorectal cancer and involves the removal of the cancerous tumour and surrounding tissues. Chemotherapy is a type of cancer treatment that uses drugs to kill cancer cells. It is often used in combination with surgery and radiation therapy to destroy any remaining cancer cells after surgery or to shrink tumours before surgery. Radiation therapy uses high-energy radiation to kill cancer cells and is often used in combination with chemotherapy to treat advanced colorectal cancer.

Targeted therapy is another type of colorectal cancer therapy that works by targeting specific proteins that are involved in the growth and spread of cancer cells. This type of therapy can be used alone or in combination with chemotherapy to treat advanced colorectal cancer. Immunotherapy is another promising treatment for colorectal cancer that works by stimulating the immune system to recognize and attack cancer cells.

The choice of colorectal cancer therapy depends on several factors, including the stage of the cancer, the location of the tumor, the patient's age and overall health, and the presence of any other medical conditions. The goal of treatment is to remove or destroy as much of the cancer as possible and to prevent its recurrence.

In summary, colorectal cancer therapeutics refer to the different treatments and medications that are used to treat colorectal cancer. These treatments may include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, and are often used in combination to achieve the best possible outcomes for patients.

Colorectal Cancer- Epidemiology, Applications, and Uses


Colorectal cancer is one of the most common types of cancer worldwide and its incidence is increasing. The epidemiology of colorectal cancer is complex and multifactorial, with several factors contributing to its development, including age, gender, lifestyle habits, and genetic factors. Epidemiological studies have shown that the incidence and prevalence of colorectal cancer varies by region, age, gender, and lifestyle habits.

Based on prevalence, the global colorectal cancer therapeutics market can be divided into several regions, including North America, Europe, Asia Pacific, and rest of the world. North America is the largest market for colorectal cancer therapeutics, owing to the high prevalence of colorectal cancer in the region. Europe is also a significant market, with a high incidence of colorectal cancer in countries such as Germany and France. The Asia Pacific region is expected to witness significant growth in the coming years, driven by the increasing prevalence of colorectal cancer and rising healthcare spending in countries like China and India.

Based on age, colorectal cancer is more common in older adults, with the highest incidence rates seen in those over the age of 50. However, there has been an increasing incidence of colorectal cancer in younger individuals in recent years.

Based on gender, men are more likely to develop colorectal cancer than women. This difference in incidence is thought to be related to lifestyle habits and hormonal factors.

Based on lifestyle habits, several factors have been linked to an increased risk of developing colorectal cancer, including a diet high in red and processed meats, a sedentary lifestyle, obesity, smoking, and alcohol consumption.

In summary, the epidemiology of colorectal cancer is complex and multifactorial, with several factors contributing to its development, including age, gender, lifestyle habits, and genetic factors. The prevalence of colorectal cancer varies by region, with North America and Europe being significant markets for colorectal cancer therapeutics. The incidence of colorectal cancer is higher in older adults, men, and those with certain lifestyle habits, such as a diet high in red and processed meats and a sedentary lifestyle. These factors are important considerations for the development and marketing of colorectal cancer therapeutics.

Colorectal Cancer Therapeutics Market- Applications


The colorectal cancer therapeutics market includes a range of treatments and medications that are used to treat colorectal cancer, which is a type of cancer that affects the colon and rectum. The main goal of these therapeutics is to remove or destroy as much of the cancer as possible and to prevent its recurrence. Colorectal cancer therapeutics are used to treat both early-stage and advanced colorectal cancer, and may include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

Surgery is the most common treatment for colorectal cancer and involves the removal of the cancerous tumour and surrounding tissues. Chemotherapy is a type of cancer treatment that uses drugs to kill cancer cells and is often used in combination with surgery and radiation therapy to destroy any remaining cancer cells after surgery, or to shrink tumours before surgery. Radiation therapy uses high-energy radiation to kill cancer cells and is often used in combination with chemotherapy to treat advanced colorectal cancer.

Targeted therapy is another type of colorectal cancer therapy that works by targeting specific proteins that are involved in the growth and spread of cancer cells. This type of therapy can be used alone or in combination with chemotherapy to treat advanced colorectal cancer. Immunotherapy is another promising treatment for colorectal cancer that works by stimulating the immune system to recognize and attack cancer cells.

Colorectal cancer therapeutics have a wide range of applications and uses, depending on the stage and location of the cancer, the patient's age and overall health, and the presence of any other medical conditions. These therapeutics are used to treat both early-stage and advanced colorectal cancer and are often used in combination to achieve the best possible outcomes for patients.

Overall, colorectal cancer therapeutics are an essential tool in the treatment of colorectal cancer and are used to remove or destroy cancerous tumours and prevent their recurrence. With the development of new and innovative cancer therapies, the future of colorectal cancer treatment looks promising, and the market for colorectal cancer therapeutics is expected to continue to grow at a steady pace.

Colorectal Cancer Therapeutics Market Segmentations


The market can be categorised into therapy, cancer type, route of administration, end user, region.

Market Breakup by Therapy
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
  • Others
Market Breakup by Cancer Type
  • Colorectal Adenocarcinoma
  • Gastrointestinal Carcinoid Tumors
  • Others
Market Breakup by Route of Administration
  • Oral
  • Parenteral
  • Others
Market Breakup by End User
  • Hospitals
  • Homecare
  • Speciality Clinics
  • Others
Market Breakup by Region
  • North America
  • United States of America
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Colorectal Cancer Therapeutics Market Scenario


The global market for colorectal cancer therapeutics is a growing segment of the pharmaceutical industry, driven by increasing prevalence of colorectal cancer, ageing population, and rising demand for effective cancer therapies. Colorectal cancer is one of the most common types of cancer worldwide and is often treated with a combination of surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

The market for colorectal cancer therapeutics is expected to continue to grow at a steady pace, driven by several factors, including increasing awareness about the benefits of early detection and treatment, the development of new and innovative cancer therapies, and the increasing adoption of these therapies in emerging markets.

North America is the largest market for colorectal cancer therapeutics, owing to the well-established healthcare infrastructure and high prevalence of colorectal cancer in the region. However, the Asia Pacific region is expected to witness significant growth in the coming years, driven by the increasing focus on healthcare development and rising demand for cost-effective medical devices. Countries like China and India are expected to be major contributors to this growth due to their large populations and increasing healthcare spending.

The market for colorectal cancer therapeutics is highly competitive, with many players offering a wide range of products to cater to the diverse needs of healthcare providers and patients. Some of the key players in the market include Roche Holding AG, Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., and Pfizer Inc.

Overall, the colorectal cancer therapeutics market is expected to continue to grow at a steady pace, driven by the increasing demand for safe and effective cancer therapies. With increasing awareness about the benefits of early detection and treatment, and the development of new and innovative cancer therapies, the adoption of colorectal cancer therapeutics is likely to increase in the coming years, further fuelling the growth of the market.

Key Players in the Global Colorectal Cancer Therapeutics Market


The report gives an in-depth analysis of the key players involved in the colorectal cancer therapeutics market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Genentech, Inc.
  • Eli Lilly and Company
  • Bayer AG
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc
  • Novartis AG
  • Accord Healthcare
  • Alkem Labs Ltd.
  • Bausch Health Companies Inc.
  • Hill Dermaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Fresenius Kabi USA
  • Sagent Pharmaceuticals, Inc.
  • Sanofi
*Please Note:* The report will be completed in 7 business days after order confirmation


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Colorectal Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Colorectal Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Colorectal Cancer Epidemiology (2016-2031)
5.3 Europe Colorectal Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Colorectal Cancer Epidemiology (2016-2031)
5.5 Latin America Colorectal Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Colorectal Cancer Epidemiology (2016-2031)
6 Global Colorectal Cancer Therapeutics Market Overview
6.1 Global Colorectal Cancer Therapeutics Market Historical Value (2016-2022)
6.2 Global Colorectal Cancer Therapeutics Market Forecast Value (2023-2031)
7 Global Colorectal Cancer Therapeutics Market Landscape
7.1 Colorectal Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Colorectal Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Therapy type
7.2.2 Analysis by Cancer Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
8 Colorectal Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Colorectal Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Colorectal Cancer Therapeutics Market Segmentation
11.1 Global Colorectal Cancer Therapeutics Market by Therapy
11.1.1 Market Overview
11.1.2 Targeted Therapy
11.1.3 Immunotherapy
11.1.4 Chemotherapy
11.1.5 Others
11.2 Global Colorectal Cancer Therapeutics Market by Cancer Type
11.2.1 Market Overview
11.2.2 Colorectal Adenocarcinoma
11.2.3 Gastrointestinal Carcinoid Tumors
11.2.4 Others
11.3 Global Colorectal Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Others
11.4 Global Colorectal Cancer Therapeutics Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Homecare
11.4.4 Specialty Clinics
11.4.5 Others
11.5 Global Colorectal Cancer Therapeutics Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Colorectal Cancer Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Colorectal Cancer Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Colorectal Cancer Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Colorectal Cancer Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Colorectal Cancer Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Genentech, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Eli Lilly and Company
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bayer AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Amgen Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 F. Hoffmann-La Roche Ltd.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Pfizer Inc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Accord Healthcare
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Alkem Labs Ltd
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Bausch Health Companies Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Hill Dermaceuticals, Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Bristol-Myers Squibb Company
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Fresenius Kabi USA
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Sagent Pharmaceuticals, Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Sanofi
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
24 Colorectal Cancer Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings